The presentation sure brought out the buyers !! I wondered why the stock action was so strong --- now I know !!! I wonder if anyone was there to listen
This is PR --- not market moving advances. Investors have limited expectations for the Ph3 results so THLD remains in the 'show me' position. If the P3 results are deemed to be significant then you will get upside.
Idiot response. Insiders are free to hedge their bets. Look at CLVS---down 70++% --- bet those insiders took some $$ off the table.
They own ZERO shares. Since when are you taking their 'guestimates' to the bank ??? most of them are rookies cutting their teeth on early stage spec biotech.
Soliris showed very strong growth up 29% in the Q. Strensiq can be a $1bil drug, with Kanuma on the ramp for FDA approval in December. Look for the analyst meeting on 12/10 to be another upside trigger as ALXN shows off their research portfolio in detail. This be $200 easily ! Next year ALXN can be up another 20-30% (in line with its growth rate).
Look for FDA approval around the corner for Kanuma for LAL-D as well. Two more $billion dollar potential products to go along with Soliris. This will push ALXN to $200+ IMHO over the short term. Look for a very +++ analyst meeting on 12/10 as ALXN gives an update on their pipeline----most investors are clueless on this.
#$%$ ! looks like somebody slipped on the ice ! looks like you may be on the wrong side of this one
JPM will be holding a call for institutional clients on Friday with RDUS management. JPM has an Overweight rating with an $85 price objective. LLY should buy RDUS & fold ABALO into their Forteo osteoarthritis franchise.
A hope &a dream---the beauty of spec biotechs. It may work out, it may not---why it's a $3-4 stock. Management hasn't done anything in the last 12-13 years so you can't bet on them. Sellick spends all him time out on the road trying to tell his story ...... not too successful.
come on now rookie---be nice. you've been predicting great things from this spec mgmt. team for the last 3 years. just because there are other small retail spec players playing the lottery dream doesn't
mean you have to get all tight in your shorts & become so #$%$. Does mommie still have a job
There are TWO imminent approvals right now at the FDA----Strensiq AND Kanuma. Both have $billion dollar sales$ potential --- and fit in nicely with a 50 nation sales force already primed & trained to go. Unless the world comes to an end in the 4Q I would say that ALXN can be approaching $200 area by year-end. People who know & follow biotech full-time recognize that you don't often get the chance to buy a company growing at 25%+ top & bottom line at a discount to its growth rate with new product sales any day now. This stock is not owned by retail.
There are many many reasons why ALXN has been one of the very top growth stocks ove the last decade & will continue to d so. Dig into the story a little more closely before your puts expire.